The Many Faces of HIV Advocacy: A Case Study of Advocacy Initiatives in the HIV/ AIDS Therapeutic Area

STUDY OVERVIEW

Patient advocacy is an effective way to create a well-informed marketplace. The HIV/AIDS pandemic presents a perfect example of how advocacy initiatives can play a vital role in educating patient groups about not only treatment options but also prevention methods. The history of HIV patient advocacy is a key chapter in the evolution of the relationship between the pharmaceutical industry and patient advocacy groups. In this case study, Best Practices LLC examines how companies such as GlaxoSmithKline, Abbott, Merck and Gilead Sciences created effective advocacy programs and relationships in response to the HIV/AIDS pandemic.


KEY TOPICS

• Timeline of HIV/AIDS Pandemic
• Building Relationships with Advocacy Groups
• Aligning with the Right Advocacy Groups
• Communicating Advocacy Support
• Extending Reach through Advocacy

• Creating & Chronicling the Multi-faceted Patient Community Is Another Way Advocacy Groups Educate

Education often begins with understanding. Gilead Sciences’s advocacy work focuses on understanding that people living with HIV have real life stories and real hope. It’s advocacy efforts focus – in part – on getting resources into the hands of people who are in different stages of treatment and managing their illness. One resource is “MyHIVLife.com”

Industries Profiled:
Pharmaceutical; Health Care; Diagnostic


Companies Profiled:
Gilead Sciences; Abbott; Merck; GlaxoSmithKline

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.